Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Grelan characterizes candidate for diabetic complications

March 20, 1997

Novel antihyperlipidemic agent from Shionogi in phase II

March 20, 1997

Wyeth-Ayerst acquires commercialization rights to rhIL-11

March 19, 1997

Cabergoline launched in U.S.

March 19, 1997

Preliminary clinical results with CI-1000

March 18, 1997

Pharmacokinetics of paracalcin in patients undergoing hemodialysis

March 18, 1997

Osiris Therapeutics awarded SBIR grant for tendon regeneration research

March 17, 1997

Genzyme Transgenics and Fresenius to further development of transgenic albumin

March 17, 1997

MGI Pharma and Schein reach marketing agreement for INFeD

March 14, 1997

MP-52 enters clinic

March 14, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...